Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AO-176 Monotherapy and Combination in Relapsed/Refractory Multiple Myeloma
NCT04445701Phase 2Completed
- Sponsor
- Arch Oncology
- Start
- Nov 2020
- Primary completion
- Aug 2022
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of AO-176 in multiple myeloma (MM), sponsored by Arch Oncology. Started Nov 2020; status: completed.
02
Drugs
AO-176
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT04445701.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04445701.